Type:3ml Cartidge
Generic Name:Insulin Glulisine
Manufacturer:Sanofi Bangladesh Ltd.
Price:৳760.00
Diabetes mellitus
SC injection Administer within 15 minutes before a meal or within 20 minutes after starting a meal When administered by SC injection, insulin glulisine should generally be used in regimens with an intermediate- or long-acting insulin Administered by SC injection in the abdominal wall, thigh, or upper arm Injection sites should be rotated within the same region (abdomen, thigh or upper arm) from one injection to the next to reduce the risk of lipodystrophy IV administration May be administered IV while under medical supervision for glycemic control with close monitoring of blood glucose and serum potassium to avoid hypoglycemia and hypokalemia When administered IV, use concentrations of 0.05-1 unit/mL in infusion systems using PVC bags Stable only in 0.9% NaCl (normal saline)
Subcutaneous Diabetes mellitus Dose should be individualised and depends on patient's needs. Usual range: 0.5-1 u/kg/day. Dosing considerations Equipotent to regular human insulin (ie, elicits same glucose lowering effects on unit per unit basis) when administered IV Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin Dosage must be individualized; blood glucose monitoring is essential in all patients receiving insulin therapy Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs Hepatic impairment: Dose reduction may be needed.
Type 1 Diabetes Mellitus Indicated to improve glycemic control in adults and children with diabetes mellitus <4 years: Safety and efficacy not established 4-17 years: May require 0.8-1.2 units/kg/day SC during growth spurts; otherwise use adult dosing (0.5-1 unit/kg/day)
Renal impairment: Dose reduction may be needed.
Hypoglycaemia.Hypersensitivity to any of the components.
Insulin glulisine is a rapid acting human insulin analog produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12). Insulin glulisine and insulin human are equipotent on a unit-for-unit basis. Insulin glulisine has a more rapid onset and shorter duration of action compared with insulin human after subcutaneous admin.
Renal or hepatic impairment. Regular monitoring of blood glucose and HbA1c. Rotate Inj sites to reduce lipodystrophy . Pregnancy, lactation. Lactation: Considered safe during breastfeeding
Hypoglycaemia, Inj site reactions, lipodystrophy, local and systemic hypersensitivity reactions.
Possible absence of hypoglycaemic warning symptoms with beta-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotics (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
